Alzheimer's Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

  • ID: 3627369
  • Report
  • Region: Global
  • 144 Pages
  • GBI Research
1 of 5
The Alzheimer’s Disease Market Will More Than Double From Just Under $5 Billion in 2014 to an Estimated $10.4 Billion in 2021

FEATURED COMPANIES

  • AFFiRiS
  • EPIX Pharma
  • GlaxoSmithKline
  • Medivation
  • Pfizer
  • Prothera
  • MORE
Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages.

The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerably high at 559. The majority of the pipeline products are novel drugs, with a total of seven repositioned and five generic drugs. This shows advancement in the progression of the different molecules being developed as therapeutic agents within the AD pipeline.

Scope

The AD market has a lack of therapeutic options.
- Which classes of drug dominate the market?
- What newly approved therapies have entered the market?
- How do the leading marketed therapies compare clinically?
- How will the new therapies be positioned in the treatment of AD?
- How have selected late-stage pipeline therapies performed in clinical trials?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.

- Which molecular targets appear most frequently in the pipeline?
AD clinical trials have an overall attrition rate of 94%.
- What are the failure rates for individual Phases of clinical development?
- How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?
The AD market is forecast to rise from a value of $5.2 billion in 2014 to $11.3 billion in 2021, at a CAGR of 11.8% across the eight major markets assessed.
- How much of a role will disease prevalence and new product approvals play in market growth?
- Will generic competition have a significant impact on the market over the forecast period?
There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.
- Which territories show the most deal activity?
- What were the trends in deal completion by product stage of development?
- What were the conditions of the key licensing or co-development deals to take place in AD?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.

- Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.

- Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

- Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

- Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AFFiRiS
  • EPIX Pharma
  • GlaxoSmithKline
  • Medivation
  • Pfizer
  • Prothera
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.6 Disease Stages
2.7 Diagnosis
2.8 Prognosis
2.9 Treatment
2.9.1 Treatment Algorithm
2.9.2 Mild-to-Moderate AD
2.9.3 Moderate-to-Severe AD

3 Marketed Products
3.1 Aricept (donepezil) - Eisai
3.2 Exelon (rivastigimine) - Novartis
3.3 Razadyne (galanatamine) - Janssen
3.4 Namenda/Ebixa/Axura/Abixa (memantine), Merz Pharma/Lundbeck/Forest/Daiichi Sankyo
3.5 Cognex (tacrine) - Shiniogi
3.6 Namzaric (memantine ER + donepezil), Actavis-Adamas

4 Heat Map - Marketed Products Overview

5 Pipeline Product Developments
5.1 The Pipeline Development Landscape
5.2 Mechanisms of Action in the Pipeline
5.3 Clinical Trials
5.3.1 Failure Rate
5.3.2 Clinical Trial Duration
5.3.3 Clinical Trial Size
5.3.4 Competitive Clinical Trials Metric Analysis
5.4 Promising Pipeline Molecules
5.4.1 MK-8931 - Merck & Co.
5.4.2 LMTX (methylthioninium chloride) - TauRX Therapeutics
5.4.3 AZD3293 - AstraZeneca
5.4.4 AB1010 - AB Science
5.4.5 BIIB037 - Biogen
5.4.6 TP488 - vTv Therapeutics
5.4.7 EVP-6124 - FORUM Pharmaceuticals
5.4.8 LuAE58054 - Lundbeck
5.4.9 Gantenerumab (R-1540/RG-1450) - Roche

6 Heat Map - Pipeline Products Overview

7 Market Forecast to 2021
7.1 Geographical Markets
7.1.1 Global Market
7.1.2 North America
7.1.3 European Union Five
7.1.4 Japan

8 Drivers and Barriers
8.1 Drivers
8.1.1 Rising Prevalence
8.1.2 Increasing Public and Policy-Maker Awareness
8.1.3 Innovation in Pipeline
8.1.4 Growing Understanding of AD Pathophysiology
8.2 Barriers
8.2.1 Sales Erosion by Generics
8.2.2 High Clinical Failure RatesAD has a particularly high clinical trial failure rate.
8.2.3 Drug Testing in Patients with Established AD and Advanced Neurodegeneration
8.2.4 Low Diagnosis and Treatment Rate

9 Strategic Consolidations
9.1 Licensing Deals
9.1.1 Cephalon Enters into Licensing Agreement
9.1.2 Lundbeck Enters into Licensing Agreement with Otsuka
9.1.3 Roche Enters into Licensing Agreement with Prothera
9.1.4 GlaxoSmithKline Enters into Licensing Agreement with AFFiRiS
9.2 Major Co-development Deals
9.2.1 Lundbeck Enters into Co-development Agreement with Otsuka
9.2.2 GlaxoSmithKline Enters into Agreement with EPIX Pharma
9.2.3 Evotec Enters into Co-development Agreement with Roche
9.2.4 Pfizer Enters into Co-development Agreement with Medivation

10 Appendix
10.1 All Pipeline Drugs by Phase
10.1.1 Discovery
10.1.2 Preclinical
10.1.3 Phase I
10.1.4 Phase II
10.1.5 Phase III
10.1.6 Market Forecasts to 2021
10.2 Bibliography
10.3 Abbreviations
10.4 Research Methodology
10.4.1 Secondary Research
10.4.2 Marketed Product Profiles
10.4.3 Late-Stage Pipeline Candidates
10.4.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
10.4.5 Product Competitiveness Framework
10.4.6 Pipeline Analysis
10.4.7 Forecasting Model
10.4.8 Deals Data Analysis
10.5 Contact Us
10.6 Disclaimer

1.1 List of Tables
Table 1: Alzheimer’s Disease Therapeutics Market, Symptoms of Alzheimer’s Disease at Different Stages of Disease
Table 2: Alzheimer’s Disease Therapeutics Market, Symptoms of Mild Cognitive Impairment
Table 3: Alzheimer’s Disease Therapeutics Market, Global Deterioration Scale for Alzheimer’s Disease
Table 4: Alzheimer’s Disease Therapeutics Market, Mini-Mental State Exam
Table 5: Alzheimer’s Disease Therapeutics Market, Alzheimer’s Disease Assessment Scale Cognitive Subscale
Table 6: Alzheimer’s Disease Therapeutics Market, Mild Cognitive Impairment Diagnosis Guidelines
Table 7: Management of AD Symptoms
Table 8: AD Market, Global, Pipeline Products, Discovery, 2016
Table 9: AD Market, Global, Pipeline Products, Preclinical, 2016
Table 10: AD Market, Global, Pipeline Products, Phase I, 2016
Table 11: AD Market, Global, Pipeline Products, Phase II, 2016
Table 12: AD Market, Global, Pipeline Products, Phase III, 2016
Table 13: MCI Market, Global, Market Forecast, 2014-2021
Table 14: AD Market, Global, Market Forecast, 2014-2021
Table 15: MCI & AD Combined Market, Global, Market Forecast, 2014-2021
Table 16: MCI Market, US, Market Forecast, 2014-2021
Table 17: AD Market, US, Market Forecast, 2014-2021
Table 18: MCI & AD Market, US, Market Forecast, 2014-2021
Table 19: MCI Market, Canada, Market Forecast, 2014-2021
Table 20: AD Market, Canada, Market Forecast, 2014-2021
Table 21: MCI & AD Combined Market, Canada, Market Forecast, 2014-2021
Table 22: MCI Market, UK, Market Forecast, 2014-2021
Table 23: AD Market, UK, Market Forecast, 2014-2021
Table 24: MCI & AD Combined Market, UK, Market Forecast, 2014-2021
Table 25: MCI Market, France, Market Forecast, 2014-2021
Table 26: AD Market, France, Market Forecast, 2014-2021
Table 27: MCI & AD Market Combined, France, Market Forecast, 2014-2021
Table 28: MCI Market, Germany, Market Forecast, 2014-2021
Table 29: AD Market, Germany, Market Forecast, 2014-2021
Table 30: MCI & AD Combined Market, Germany, Market Forecast, 2014-2021
Table 31: MCI Market, Italy, Market Forecast, 2014-2021
Table 32: AD Market, Italy, Market Forecast, 2014-2021
Table 33: MCI & AD Combined Market, Italy, Market Forecast, 2014-2021
Table 34: MCI Market, Spain, Market Forecast, 2014-2021
Table 35: AD Market, Spain, Market Forecast, 2014-2021
Table 36: MCI & AD Combined Market, Spain, Market Forecast, 2014-2021
Table 37: MCI Market, Japan, Market Forecast, 2014-2021
Table 38: AD Market, Japan, Market Forecast, 2014-2021
Table 39: MCI & AD Combined Market, Japan, Market Forecast, 2014-2021

1.2 List of Figures
Figure 1: Alzheimer’s Disease Therapeutics Market, Treatment Algorithm of Alzheimer’s Disease
Figure 2: Alzheimer’s Disease Therapeutics Market, Heat Map for Marketed Products
Figure 3: Alzheimer’s Disease Therapeutics Market, Overall Pipeline
Figure 4: Alzheimer’s Disease Therapeutics Market, Pipeline by Mechanism of Action (%)
Figure 5: Alzheimer’s Disease Therapeutics Market, Clinical Trial Failure Rates by Phase (%)
Figure 6: Alzheimer’s Disease Therapeutics Market, Clinical Trial Failure Rates by Mechanism of Action, (%)
Figure 7: Alzheimer’s Disease Therapeutics Market, Clinical Trial Duration by Molecule Type (months)
Figure 8: Alzheimer’s Disease Therapeutics Market, Clinical Trial Duration by Mechanism of Action (months)
Figure 9: Alzheimer’s Disease Therapeutics Market, Clinical Trial Size per Product by Molecule Type (participants)
Figure 10: Alzheimer’s Disease Therapeutics Market, Clinical Trial Size per Product by Mechanism of Action (participants)
Figure 11: Alzheimer’s Disease Therapeutics Market, Clinical Trial Size per Trial by Molecule Type (participants)
Figure 12: Alzheimer’s Disease Therapeutics Market, Clinical Trial Size per Trial by Mechanism of Action (participants)
Figure 13: Alzheimer’s Disease Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 14: Alzheimer’s Disease Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Mechanism of Action
Figure 15: Alzheimer’s Disease Therapeutics Market, Global, Verubecestat Market Forecast ($m), 2018-2021
Figure 16: Alzheimer’s Disease Therapeutics Market, Global, LMTX Market Forecast ($m), 2017-2021
Figure 17: Alzheimer’s Disease Market, Global, AZD3293 Market Forecast ($m), 2019-2021
Figure 18: Alzheimer’s Disease Therapeutics Market, Global, Masitinib Market Forecast ($m), 2017-2021
Figure 19: Alzheimer’s Disease Therapeutics Market, Global, Aducanumab Market Forecast ($m), 2019-2021
Figure 20: Alzheimer’s Disease Therapeutics Market, Global, Azeliragon Market Forecast ($m), 2017-2021
Figure 21: Alzheimer’s Disease Therapeutics Market, Global, Encenicline Hydrochloride Market Forecast ($m), 2017-2021
Figure 22: Alzheimer’s Disease Therapeutics Market, Global, Idalopirdine Market Forecast ($m), 2017-2021
Figure 23: Alzheimer’s Disease Therapeutics Market, Global, Gantenerumab Market Forecast ($m), 2020-2021
Figure 24: Alzheimer’s Disease Therapeutics Market, Heat Map for Marketed Products
Figure 25: Alzheimer’s Disease and Mild Cognitive Impairment Therapeutics Markets, Global, Treatment Patterns (‘000), 2014-2021
Figure 26: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Global, Treatment Patterns (‘000), 2014-2021
Figure 27: Alzheimer’s Disease and Mild Cognitive Impairment Therapeutics Markets, Global, Market Size ($bn), 2014-2021
Figure 28: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Global, Market Size ($bn), 2014-2021
Figure 29: Alzheimer’s Disease and Mild Cognitive Impairment Therapeutics Markets, North America, Treatment Patterns (‘000), 2014-2021
Figure 30: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, North America, Treatment Patterns (‘000), 2014-2021
Figure 31: Alzheimer’s Disease Therapeutics Market, North America, Annual Cost of Therapy ($), 2014-2021
Figure 32: Alzheimer’s Disease Therapeutics Market, North America, Market Size ($m), 2014-2021
Figure 33: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, North America, Market Size, 2014-2021
Figure 34: Mild Cognitive Impairment Therapeutics Market, EU5, Treatment Patterns (‘000), 2014-2021
Figure 35: Alzheimer’s Disease Therapeutics Market, EU5, Treatment Patterns (‘000), 2014-2021
Figure 36: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, EU5, Treatment Patterns (‘000), 2014-2021
Figure 37: Mild Cognitive Impairment Therapeutics Market, EU5, Annual Cost of Therapy ($), 2014-2021
Figure 38: Alzheimer’s Disease Therapeutics Market, EU5, Annual Cost of Therapy ($), 2014-2021
Figure 39: Mild Cognitive Impairment Therapeutics Market, EU5, Market Size ($m), 2014-2021
Figure 40: Alzheimer’s Disease Therapeutics Market, EU5, Market Size ($m), 2014-2021
Figure 41: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, EU5, Market Size ($m), 2014-2021
Figure 42: Alzheimer’s Disease and Mild Cognitive Impairment Therapeutics Markets, Japan, Treatment Patterns (‘000), 2014-2021
Figure 43: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Japan, Treatment Patterns (‘000), 2014-2021
Figure 44: Mild Cognitive Impairment Therapeutics Market, Japan, Annual Cost of Therapy ($), 2014-2021
Figure 45: Alzheimer’s Disease Therapeutics Market, Japan, Annual Cost of Therapy ($), 2014-2021
Figure 46: Mild Cognitive Impairment Therapeutics Market, Japan, Market Size ($bn), 2014-2021
Figure 47: Alzheimer’s Disease Therapeutics Market, Japan, Market Size ($m), 2014-2021
Figure 48: Alzheimer’s Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Japan, Market Size ($bn), 2014-2021
Figure 49: Alzheimer’s Disease Therapeutics Market, Licensing Deals by Value, 2006-2015
Figure 50: Alzheimer’s Disease Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($bn) and Aggregate Upfront Payment Value ($bn), 2006-2015
Figure 51: Alzheimer’s Disease Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
Figure 52: Alzheimer’s Disease Therapeutics Market, Global, Licensing Deals by Molecule Type and Value ($), 2006-2015
Figure 53: Alzheimer’s Disease Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Value ($bn), 2006-2015
Figure 54: Alzheimer’s Disease Therapeutics Market, Global, Co-development Deals by Value, 2006-2015
Figure 55: Alzheimer’s Disease Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2015
Figure 56: Alzheimer’s Disease Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($) and Upfront Payment Value ($m), 2006-2015
Figure 57: Alzheimer’s Disease Therapeutics Market, Global, Co-development Deals by Molecule Type and Value ($), 2006-2015
Figure 58: Alzheimer’s Disease Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Value ($bn), 2006-2015

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AFFiRiS
- Cephalon
- EPIX Pharma
- Evotec
- GlaxoSmithKline
- Lundbeck
- Medivation
- Otsuka
- Pfizer
- Pharma
- Prothera
- Roche
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll